Alpha Tau Medical Ltd., a developer of innovative alpha-radiation cancer therapy, has announced the successful treatment of the first patient in its U.S. multi-center pilot study for pancreatic cancer, known as IMPACT. This study is evaluating the safety, feasibility, and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma. The trial utilizes a non-surgical, minimally invasive approach to deliver Alpha DaRT sources directly into the pancreatic tumor under real-time endoscopic ultrasound guidance. The study is part of Alpha Tau's broader strategy to address unmet needs in cancer treatment. Results from the study have not yet been presented; the focus is on generating high-quality clinical data to inform future development.